{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:39:06Z","timestamp":1787243946321,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12185-025-03980-8","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:52:52Z","timestamp":1743486772000},"page":"224-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone"],"prefix":"10.1007","volume":"122","author":[{"given":"Yuichi","family":"Horigome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Michishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Tadera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8438-2186","authenticated-orcid":false,"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"11","key":"3980_CR1","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/s1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396. https:\/\/doi.org\/10.1016\/s1470-2045(21)00466-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3980_CR2","doi-asserted-by":"publisher","first-page":"ofx007","DOI":"10.1093\/ofid\/ofx007","volume":"4","author":"K Shiraki","year":"2017","unstructured":"Shiraki K, Toyama N, Daikoku T, Yajima M. Herpes Zoster and Recurrent Herpes Zoster. Open Forum Infect Dis. 2017;4(1):ofx007. https:\/\/doi.org\/10.1093\/ofid\/ofx007.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"3980_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bj\u00f6rkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107\u201313. https:\/\/doi.org\/10.3324\/haematol.2014.107714.","journal-title":"Haematologica"},{"issue":"9","key":"3980_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906\u201317. https:\/\/doi.org\/10.1056\/NEJMoa0801479.","journal-title":"N Engl J Med"},{"issue":"8","key":"3980_CR5","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3980_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"3980_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224\u201333. https:\/\/doi.org\/10.1038\/s41375-019-0539-0.","journal-title":"Leukemia"},{"issue":"23","key":"3980_CR8","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf T, Xu XS, Adams HC III, Axel AE, Chiu C, Khan I, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1(23):2105\u201314. https:\/\/doi.org\/10.1182\/bloodadvances.2017006866.","journal-title":"Blood Adv"},{"issue":"2","key":"3980_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211927","volume":"14","author":"H Nahi","year":"2019","unstructured":"Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS ONE. 2019;14(2): e0211927. https:\/\/doi.org\/10.1371\/journal.pone.0211927.","journal-title":"PLoS ONE"},{"key":"3980_CR10","unstructured":"Prevention and treatment of cancer-related infections ver.1.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf"},{"issue":"12","key":"3980_CR11","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","volume":"92","author":"K Kawai","year":"2017","unstructured":"Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806\u201321. https:\/\/doi.org\/10.1016\/j.mayocp.2017.10.009.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"3980_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.13532","volume":"171","author":"BW Teh","year":"2015","unstructured":"Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171(1):100\u20138. https:\/\/doi.org\/10.1111\/bjh.13532.","journal-title":"Br J Haematol"},{"issue":"6","key":"3980_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6): e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833.","journal-title":"BMJ Open"},{"issue":"1","key":"3980_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40261-017-0581-5","volume":"38","author":"A Mizukami","year":"2018","unstructured":"Mizukami A, Sato K, Adachi K, Matthews S, Holl K, Matsuki T, et al. Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in japanese adults aged 60 years or older: results from a prospective. Observ Cohort Study Clin Drug Investig. 2018;38(1):29\u201337. https:\/\/doi.org\/10.1007\/s40261-017-0581-5.","journal-title":"Observ Cohort Study Clin Drug Investig"},{"issue":"12","key":"3980_CR15","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.vaccine.2018.02.029","volume":"36","author":"M Kovac","year":"2018","unstructured":"Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, et al. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018;36(12):1537\u201341. https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.029.","journal-title":"Vaccine"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03980-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03980-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03980-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:06:40Z","timestamp":1753906000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03980-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3980"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03980-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YH received honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb, and Sanofi. HK received honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb, and Sanofi. NT received honoraria from Sanofi. KH received honoraria from Bristol-Myers Squibb. TS received honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb, and Sanofi. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}